

**MT2023-31: A multi-center, randomized, active controlled clinical trial to evaluate the efficacy and safety of OTL-203 in subjects with mucopolysaccharidosis type I, Hurler syndrome (MPS-IH) compared to standard of care with allogeneic hematopoietic stem cell transplantation (allo-HSCT)**

**Status:** Recruiting

## Eligibility Criteria

**Sex:** Male or Female

**Age Group:** Up to 18 years old

This study is NOT accepting healthy volunteers

### Inclusion Criteria:

- at least 28 days old to no more than 30 months old - confirmed laboratory diagnosis of MPS-IH - evidence of altered GAG metabolism - see link to [clinicaltrials.gov](https://clinicaltrials.gov) for complete inclusion and exclusion criteria

---

### Exclusion Criteria:

- previous allo-HSCT or gene therapy - diagnosis of HIV, Hepatitis B, Hepatitis C, or Mycoplasma - history of uncontrolled seizures - contraindications for MRI scans - study staff will review additional exclusion criteria

## Conditions & Interventions

### Conditions:

Rare Diseases

### Keywords:

Hurler syndrome, MPS-IH, mucopolysaccharidosis type I

## More Information

**Description:** This research study is designed to compare a new gene therapy, known as OTL-203 (study drug), with a standard treatment called "allogeneic hematopoietic stem cell transplant" (allo-HSCT), to find out which is better for the treatment of MPS-IH.

**Study Contact:** Ashish Gupta - [gupta461@umn.edu](mailto:gupta461@umn.edu)

**Principal Investigator:** Ashish Gupta

### IRB

**Number:** STUDY00020015

---

Thank you for choosing StudyFinder. Please visit <http://studyfinder.umn.edu> to find a Study which is right for you and contact [sfinder@umn.edu](mailto:sfinder@umn.edu) if you have questions or need assistance.